Cargando…

TP53 variants in p53 signatures and the clonality of STICs in RRSO samples

OBJECTIVE: Precursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of BRCA1/2. Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of high-grade serous carcinoma, whereas the significance o...

Descripción completa

Detalles Bibliográficos
Autores principales: Akahane, Tomoko, Masuda, Kenta, Hirasawa, Akira, Kobayashi, Yusuke, Ueki, Arisa, Kawaida, Miho, Misu, Kumiko, Nakamura, Kohei, Nagai, Shimpei, Chiyoda, Tatsuyuki, Yamagami, Wataru, Hayashi, Shigenori, Kataoka, Fumio, Banno, Kouji, Sugano, Kokichi, Okita, Hajime, Kosaki, Kenjiro, Nishihara, Hiroshi, Aoki, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250861/
https://www.ncbi.nlm.nih.gov/pubmed/35557033
http://dx.doi.org/10.3802/jgo.2022.33.e50
Descripción
Sumario:OBJECTIVE: Precursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of BRCA1/2. Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of high-grade serous carcinoma, whereas the significance of the p53 signature remains unclear. In this study, we investigated the relationship between the p53 signature and the risk of ovarian cancer. METHODS: We analyzed the clinicopathological findings and conducted DNA sequencing for TP53 variants of p53 signatures and STIC lesions isolated using laser capture microdissection in 13 patients with pathogenic variants of BRCA1/2 who underwent RRSO and 17 control patients with the benign gynecologic disease. RESULTS: TP53 pathogenic variants were detected significantly higher in RRSO group than control (p<0.001). No difference in the frequency of p53 signatures were observed between groups (53.8% vs 29.4%; p=0.17). TP53 sequencing and next-generation sequencing analysis in a patient with STIC and occult cancer revealed 2 TP53 mutations causing different p53 staining for STICs and another TP53 mutation shared between STIC and occult cancer. CONCLUSION: The sequence analysis for TP53 revealed 2 types of p53 signatures, one with a risk of progression to STIC and ovarian cancer with pathological variants in TP53 and the other with a low risk of progression without pathological variants in TP53 as seen in control.